Description
Present and Future Dyslipidemia Therapies for Reducing Cardiovascular Risk and Cardiovascular Disease Incidence
Coordinator: Rashid Shirya
Language: EnglishSubjects for Present and Future Dyslipidemia Therapies for Reducing...:
160 p. · 15x22.8 cm · Paperback
Description
/li>Contents
/li>Biography
/li>Comment
/li>
In the last few decades, statins had been widely used to successfully lower ASCVD risk. Despite the efficacy of statins in reducing CVD events in primary and secondary prevention patients, there is still substantial residual risk and initial and recurring CVD events remaining in these patient groups.
Dyslipidemia Therapies for Reducing Cardiovascular Disease Risk provides an overview of the latest research and developments in dyslipidemia therapies to combat elevated lipid levels leading to atherosclerotic cardiovascular disease (ASCVD). A translational medicine approach is used to discuss the background on key lipid disorders in the population leading to cardiovascular disease; clinical trial development of the new drug therapies to combat the lipid disorders and their mechanisms of action; and the target patient groups of the therapies and how they address unmet medical needs in cardiovascular disease/lipid disorders. Contributions from leaders in the dyslipidemia, metabolic and cardiology fields, they offer insights into the research and development and medical backgrounds of the new drug therapies, as well as unpublished information regarding the challenges in unmet medical needs with respect to dyslipidemia in the population, clinical trial development of the therapies and future goals for the therapies.
2. The role of established therapies for LDL-cholesterol lowering – statins and ezetimibe
3. PCSK9 monoclonal antibodies and LDL-cholesterol lowering
4. PCSK9 siRNAs as novel therapy for elevated LDL-cholesterol in patients at cardiovascular disease risk
5. Bempadoic Acid as a novel pathway targeting LDL-cholesterol
6. The Role of CETP inhibitors in LDL-cholesterol lowering
7. Beyond LDL-cholesterol, Lp(a) as a therapeutic target
8. Beyond LDL-cholesterol, triglycerides as a therapeutic target effectively reduced by icosapent ethyl
9. Beyond LDL-cholesterol, novel targets: apoCIII, MTP, endothelial lipase and AngPTL3 inhibitors
- Fills the knowledge gap in the range and prevalence of dyslipiddemias in the population - both common and rare dyslipdemias - and the appropriate current therapies to manage these lipid disorders
- Get up-to-date with the rapidly evolving research/translational medicine, clinical trials for new and emerging therapies on the horizon and new FDA approved drugs being implemented globally
- Thought leaders in the field provides unpublished insights on the dyslipidemia field, its challenges and goals and what’s in the horizon for patient therapies and, further, the best approach to use for patient management in this complex area of cardiology
These books may interest you
Combination Therapy In Dyslipidemia 105.49 €
Genetics of Dyslipidemia 158.24 €